LEADS BIOLABS-B (09887) has announced that its pivotal registrational Phase IIb study evaluating Vilitrin (Opasci sumab, PD-L1/4-1BB bispecific antibody) as a monotherapy for advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) has been selected for a Late-Breaking Abstract (LBA) at the 2026 ESMO Annual Congress. The study has also earned a Proffered Paper presentation slot, underscoring its breakthrough innovative nature and substantial clinical value, with findings poised to transform existing clinical practice and reshape the standard treatment landscape for advanced EP-NEC.
Notably, LEADS BIOLABS-B has secured three Proffered Paper presentation slots at ESMO 2026, ranking among the highest number of selections for Chinese pharmaceutical companies. The details of the LBA-selected study are as follows: Title: Opasci sumab (LBL-024) monotherapy for previously treated advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) after two or more lines of therapy: results from a pivotal registrational Phase IIb study of a novel PD-L1x4-1BB bispecific antibody. Presentation format: Proffered Paper; Principal Investigator: Professor Shen Lin, Peking University Cancer Hospital; Presenter: Director Lu Ming, Peking University Cancer Hospital; Presentation time: October 26, 10:15-10:25 AM local time.
The pivotal Phase IIb study selected for LBA at ESMO aims to evaluate the efficacy and safety of Vilitrin monotherapy in patients with advanced EP-NEC who have received at least two prior lines of systemic therapy. The study data serves as core support for the company's submission of a New Drug Application (NDA) to relevant regulatory authorities.
At ESMO 2026, LEADS BIOLABS-B achieved three Proffered Paper presentation qualifications, including: (i) the pivotal registrational Phase IIb study of Vilitrin monotherapy for advanced EP-NEC (selected for LBA); (ii) a Phase Ib/II study of Vilitrin in combination with chemotherapy as first-line treatment for EP-NEC; and (iii) a Phase I study of LBL-034 in relapsed or refractory multiple myeloma (RRMM).
Proffered Paper represents one of ESMO's highest-tier oral presentation categories, granted exclusively to original research data of exceptional quality, reflecting the international oncology community's recognition of the study's innovation, data integrity, and clinical significance. Having three studies selected for Proffered Paper presentations at ESMO 2026 is not merely a breakthrough at the individual study level but a comprehensive endorsement of the company's innovation capabilities, clinical development system, and multi-tumor-type pipeline strategy, fully demonstrating its capacity to consistently generate high-caliber clinical research and compete on the international academic stage.
Additionally, LEADS BIOLABS-B has four additional high-quality studies accepted for poster presentations at the congress, covering Vilitrin clinical research in biliary tract cancer (BTC), mechanistic studies in microsatellite stable colorectal cancer, and several meta-analyses, showcasing the company's refined and diversified research and development framework across both clinical exploration in solid tumors and systematic literature reviews.
Comments